Intravenous Immunoglobulin (IVIG) Market Set to Reach USD 40.8 Billion by 2034, Dominated by North America with 54% Global Share | DataM Intelligence

The global Intravenous Immunoglobulin (IVIG) market size is estimated at approximately USD 18.7 billion in 2025 and is projected to reach about USD 40.8 billion by 2034, growing at a CAGR of around 9.1% during this period

due to increasing prevalence of autoimmune and immunodeficiency disorders, rising demand for immunotherapy treatments, advancements in IVIG formulations, and expanding healthcare access worldwide.

Download your exclusive sample report today: (corporate email gets priority access):https://www.datamintelligence.com/download-sample/intravenous-immunoglobulin-market?pratik

U.S Industry Development

✅ The U.S. intravenous immunoglobulin (IVIG) market was valued at around USD 16.03 billion in 2024 and is projected to grow with a CAGR of approximately 8.6% from 2025 to 2034.

✅ North America generated more than 47% of the global revenue share in 2024, with the U.S. dominating due to a highly developed healthcare infrastructure and a large plasma collection network.

✅ IVIG usage is increasingly expanding in the U.S. especially for neurological conditions such as Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Guillain-Barré Syndrome, and multiple sclerosis.

✅ Prominent pharmaceutical companies, including Baxter International Inc., drive growth by introducing innovative and effective IVIG drugs, supported by robust research, clinical trials, and marketing efforts.

Japan Industry Deevloment

✅ The Japan IVIG market was valued at approximately USD 2.1 billion in 2024 and is forecast to grow at a CAGR of about 7.7%-7.8% from 2025 to 2032, reaching an estimated USD 3.8 billion by 2032.

✅ Growth is driven by Japan's aging population, increasing diagnosis and awareness of immunological disorders including autoimmune diseases and primary immunodeficiencies, and a mature healthcare infrastructure.

✅ Technological advancements include higher-concentration IVIG formulations that reduce infusion volume and treatment time, enhancing patient compliance and comfort. Also, there is growing development of subcutaneous immunoglobulin (SCIG) therapies for home administration.

✅ The regulatory environment supports high product quality and safety but can prolong approval processes, emphasizing the importance of localized clinical trials and tailored formulations for the Japanese market.

➠ Market segmentation

»By Therapeutic Area:

Primary Immunodeficiency (PID) is the largest segment due to increasing diagnosis and awareness.

Other major therapeutic segments include Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Guillain-Barré Syndrome (GBS), Immune Thrombocytopenic Purpura (ITP), and Multifocal Motor Neuropathy (MMN).

»By Dosage Form:

The market is segmented into liquid and lyophilized forms.

Liquid IVIG formulations are preferred for ease of administration.

»BY Type of Immunoglobulin:

IgG dominates the market, accounting for around 74.75% of revenue due to its critical role in replacement and immunomodulation therapy.

Other immunoglobulins include IgA, IgM, IgE, and IgD, but these constitute smaller shares.

"Secure your 30% year-end discount - get this report before the offer expires."
:https://www.datamintelligence.com/buy-now-page?report=intravenous-immunoglobulin-market?pratik ((Purchase 2 or more Repots and get 50% Discount)

➠ Regional insights-

»North America:

North America is the largest region, accounting for about 42-57% of the global IVIG market share in 2024-2025.

The U.S. leads this market due to a highly developed healthcare system, extensive plasma collection networks, and growing demand for IVIG therapies for immunodeficiency and neurological disorders.

The market here grows steadily with a CAGR around 7-9% and benefits from strong investments, favorable reimbursement policies, and rising clinician adoption.

»Asia-Pacific:

Asia-Pacific is the fastest-growing region, with a CAGR of approximately 8.4% to 9.1% through 2030.

Key markets include China, Japan, India, and South Korea.

Growth drivers are aging population, increased diagnosis of primary immunodeficiency diseases, healthcare spending, reimbursement expansion, and local production incentives.

China shows significant price reductions due to National Reimbursement Drug List negotiations, expanding patient access.

Japan maintains market growth with advanced biologics adoption and health technology assessments supporting funding.

»Europe:

Europe holds a notable market share but less than North America.

Growth is steady, supported by healthcare infrastructure, aging population, and increasing diagnosis rates.

Countries like Germany, France, Italy, and the UK are key contributors.

➠ Emerging players :-

»Hualan Biological Engineering Inc. (China): Expanding globally with WHO-prequalified lyophilized IVIG products and enhancing virus inactivation methods beyond regulatory requirements.

»Shanghai RAAS Blood Products Co., Ltd. (China): Major exporter of lyophilized IVIG, particularly to Africa, Latin America, and Southeast Asia, with advanced plasma collection and manufacturing technologies.

»China Biologic Products Holdings, Inc. (CBPO) (China): Rapidly growing through acquisitions with GMP-certified facilities and expanding plasma collection infrastructure.

»LFB Group (France): Focuses on specialized lyophilized IVIG products targeting specific neurological indications and maintains strategic partnerships in Europe.

»Kedrion S.p.A. (Italy): Concentrates on the European and emerging markets with integrated plasma collection and optimization of manufacturing yields.

Get Customization in the report as per your requirements:https://www.datamintelligence.com/customize/intravenous-immunoglobulin-market?pratik

➠Key Investment:

»North America dominates the market, generating more than 47% of global revenue in 2024, driven by advanced healthcare infrastructure and major pharmaceutical players investing heavily in research and development, clinical trials, and marketing.​

»The U.S. IVIG market alone was valued at USD 16.03 billion in 2024 with a projected CAGR of 8.6% through 2034, reflecting strong domestic investment in capacity expansion and innovation.​

»Key investment trends include expansions in plasma collection centers to meet increasing demand, supported by major producers such as Takeda Pharmaceutical Company Limited , Grifols, S.A. , CSL Limited , Octapharma AG (Switzerland), and Pfizer Inc. .​

»Innovations attracting investment include development of high-concentration IVIG formulations, rapid infusion protocols, and home-based infusion programs, enhancing patient convenience and clinic efficiency.​

➠Growth Drivers:-

»Expanding adoption of IVIG treatments for off-label indications such as Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Guillain-Barré Syndrome, Immune Thrombocytopenic Purpura (ITP), and Kawasaki disease.

»Growing geriatric population globally, which is more prone to immunological disorders requiring IVIG therapy.

»Technological advancements in IVIG products, including higher concentration formulations, faster infusion protocols, and personalized medicine approaches, improving therapy efficacy and patient compliance.

»Increasing awareness and diagnosis rates driven by improved healthcare infrastructure and medical screening, especially in emerging markets like Asia-Pacific.

Unlock 360° Market Intelligence with DataM Subscription Services:
https://www.datamintelligence.com/reports-subscription?sp

✅ Competitive Landscape
✅ Technology Roadmap Analysis
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Consumer Behavior & Demand Analysis
✅ Import-Export Data Monitoring
✅ Live Market & Pricing Trends

Have a look at our Subscription Dashboard:
https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.